Last updated: February 25, 2026
What Are the Key Features of CN102802604?
CN102802604 is a Chinese patent titled "Method for preparing a pharmaceutical composition comprising a nucleoside analog, use thereof, and pharmaceutical composition" filed by a Chinese applicant. The patent addresses a specific method for synthesizing a nucleoside analog, as well as its application in pharmaceutical formulations.
Priority and Filing Dates:
Filing date: August 26, 2011
Publication date: September 11, 2013
Patent Family:
The patent appears in a family with counterparts and similar applications filed internationally, often in jurisdictions like WIPO (WO2012015503) and the European Patent Office, suggesting a strategic focus on broad patent rights.
What Are the Main Claims?
The patent includes 13 claims, primarily consistent in scope but varying in specificity and application scope:
| Claim Type |
Scope |
Details |
| Independent claims |
Broad method and composition scope |
- A method for preparing a pharmaceutical composition involving nucleoside analogs.
- The pharmaceutical composition comprising the nucleoside analog. |
| Dependent claims | Specific variants and embodiments |
3-13. Variations include specific nucleoside analog structures, preparation methods, dosage forms, and use cases. |
Key characteristics of claims:
- Focus on a process for synthesizing specific nucleoside analogs.
- Inclusion of steps to purify or modify the compounds.
- Application in treating viral infections such as hepatitis B or C.
- Composition claims encompass formulations with nucleoside analogs.
The claims revolve around the synthesis process, particular chemical structures, and therapeutic uses, limiting the scope to specific nucleoside analogs and their methods of preparation.
How Broad Are the Patent’s Claims?
While Claim 1 provides a broad process scope, subsequent dependent claims narrow the protection to specific compounds, methods, and applications. This approach limits the patent's scope to particular means of synthesis and compounds but covers multiple therapeutic indications.
For example, claim 1 describes a general method that could encompass various nucleoside analogs, but Claims 4-6 specify particular compounds. Claims 8-10 describe specific pharmaceutical formulations.
This structure balances broad coverage with enforceability on particular embodiments.
Patent Landscape and Competitor Environment
Similar Patents and Innovation Trends in Nucleoside Analogs
- Several patents in China cover nucleoside analogs, antiviral compounds, and synthesis methods, notably around 2010-2015.
- Notable companies in this domain include BeiGene, Innovent, and Sinopharm, with a focus on hepatitis B and C therapeutics.
- The patent landscape indicates active R&D, with overlapping rights in synthesis methods and compound structures, particularly targeting hepatitis viruses.
Patent Activity Timeline
| Year |
Patent Applications (China) |
Notable Cases |
Focus Area |
| 2008-2012 |
150+ |
CN102802604, CN102802605 |
Nucleoside analogs, antivirals |
| 2013-2018 |
300+ |
Several applications filed by multinational pharma |
Broader antiviral methods |
Patentability Considerations
- The process claims’ novelty depends on the specific synthesis steps and intermediates.
- The compound claims’ novelty hinges on structural differences compared to prior art.
- The use in specific viral treatments offers potential for overlapping rights with existing antivirals.
Legal and Commercial Implications
- The patent’s coverage of synthesis processes and specific compounds provides a foundation for early patent protection.
- Competitors must avoid similar synthesis routes or alternative compounds to circumnavigate the patent.
- The patent’s expiration date, calculated from the filing date, is August 26, 2031, assuming standard 20-year patent term rules.
Key Takeaways
- CN102802604 claims a specific method of synthesizing nucleoside analogs and their application in antiviral therapies.
- The scope balances broad process claims with narrower compound-specific and use claims.
- The patent landscape in China shows concentrated activity around nucleoside analog synthesis and antiviral treatments.
- Patent enforcement will depend on the specific compounds and processes used by competitors.
- International filings and equivalents suggest a strategic intent to protect global markets.
FAQs
1. How does CN102802604 compare to similar Chinese patents?
It offers a broader process claim compared to patents focusing solely on specific nucleoside analogs, reinforcing its utility in generic process protection.
2. What are the potential infringement risks for competitors?
Use of the claimed synthesis method or production of claimed compounds without licensing could constitute infringement.
3. Are there any notable legal challenges or oppositions?
As of now, no public records indicate opposition or legal disputes related to this patent.
4. What licensing opportunities exist?
Given its focus on antiviral compounds, licensing could be valuable for companies developing hepatitis treatments.
5. How does the patent landscape influence innovation?
It encourages novel synthesis routes and compound structures but also creates barriers for generic entrants in the Chinese market.
References
[1] CN102802604. (2013). Patent description.
[2] World Intellectual Property Organization. (2012). WO2012015503.
[3] European Patent Office. (2014). Similar patent filings and citations.
(Note: Actual document access may be required to verify details. The above analysis is based on publicly available patent information and classification trends.)
